

April 28, 2022
Announcement no. 9

BioPorto A/S - Annual General Meeting

Today, BioPorto A/S held its Annual General Meeting.

The general meeting resolved to conduct the meeting in English without simultaneous interpretation into Danish. Subsequently, the report on the Company's activities was noted and the 2021 Annual Report was adopted, including the proposed allocation of the results. Discharge of liability was granted to the Board of Directors and the Executive Management, and the 2021 Remuneration Report was approved by advisory vote.

The remuneration for the Board of Directors for the financial year 2022 and a related amendment to the Remuneration Policy was also approved.

Christopher Lindop, John McDonough, Jan Leth Christensen, Peter Mørch Eriksen, Dr. Michael S. Singer and Don M. Hardison were re-elected as members of the Board of Directors.

The proposals from the Board of Directors under item 9 of the agenda were all adopted and included: a) Renewal of the authorisation to increase the share capital, subject to a limit of DKK 125,000,000 for pre-emptive issues and a limit of DKK 37,500,000 for issues without pre-emptive rights with the option of an additional DKK 87,500,000 for offerings where the new shares are admitted to trading on a stock exchange, etc. other than Nasdaq Copenhagen, b) Authorisation to hold general meetings as either partly or fully electronic general meetings, c) Authorisation for general meetings to be conducted in English, d) Inclusion of the name of the Company's keeper of the register of shareholders in the Articles of Association, and e) Authorisation to the Chairman of the general meeting.

PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab was re-elected as the Company's auditor.

Immediately following the Annual General Meeting, the Board of Directors elected Christopher Lindop as Chairman and John McDonough as Vice Chairman.

Hellerup, April 28, 2022
BioPorto A/S
The Board of Directors

For further information, please contact:

Tony Pare, CEO
Neil Goldman, Executive VP & CFO
Tim Eriksen, Zenith Advisory

Telephone +45 4529 0000, e-mail: investor@bioporto.com

About BioPorto

BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers - tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company's tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.

The Company's flagship product is The NGAL Test, which has been designed to aid in the risk assessment of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality if not identified and treated early. With the aid of The NGAL Test, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies.

BioPorto is headquartered in Hellerup, Denmark and is listed on the Nasdaq Copenhagen stock exchange [CPH:BIOPOR].